MedTrace Logo

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

NCT04502082 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-09-08

No results posted yet for this study

Summary

Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

Conditions

Interventions

BIOLOGICAL

ET140203 autologous T cell product

Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

Sponsors & Collaborators

  • Eureka Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Pei Wang, PhD · Eureka Therapeutics Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-14
Primary Completion
2024-08-30
Completion
2024-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04502082 on ClinicalTrials.gov